Announcements Trials
Browse Landscape

Status

Completed 182Terminated 88Recruiting 64Active not recruiting 44Unknown 28Withdrawn 19Not yet recruiting 7Available 3Approved for marketing 3Suspended 1No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Expanded_access 3

Sponsor

Cancer Type

Lymphoid 3Sarcoma 1Plasma cell 1Myeloid 1Gynecologic 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Pancreatic Neoplasms 5Multiple Myeloma 5Melanoma 5Prostatic Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Glioblastoma 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Recurrence 2Primary Myelofibrosis 2Non-Muscle Invasive Bladder Neoplasms 2Neuroblastoma 2Neoplasm Metastasis 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Lymphoma 2Head and Neck Neoplasms 2Gastrointestinal Neoplasms 2Colorectal Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2

Interventions

selinexor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Available × INDUSTRY × Lymphoma, Large B-Cell, Diffuse × Clear all
NCT07215832 2026-03-02

KEAP

Karyopharm Therapeutics Inc

Available
GynecologicLymphoidMyeloidPlasma cellSarcoma

Multiple Myeloma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Endometrial Neoplasms, Primary Myelofibrosis

NCT05619367 2025-12-23

A Compassionate Use (CU) Program of Odronextamab

Regeneron Pharmaceuticals

Available
Lymphoid

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04400591 2025-12-11

Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol

Juno Therapeutics, a Subsidiary of Celgene

Available
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡